CR20220312A - Compuestos tricíclicos sustituidos - Google Patents

Compuestos tricíclicos sustituidos

Info

Publication number
CR20220312A
CR20220312A CR20220312A CR20220312A CR20220312A CR 20220312 A CR20220312 A CR 20220312A CR 20220312 A CR20220312 A CR 20220312A CR 20220312 A CR20220312 A CR 20220312A CR 20220312 A CR20220312 A CR 20220312A
Authority
CR
Costa Rica
Prior art keywords
compound
formula
rasopathies
infectious
disorders
Prior art date
Application number
CR20220312A
Other languages
English (en)
Inventor
Ganesh Kakade
Nilesh Raghunath Khedkar
Vikas Sitaram Tambe
Samiron Phukan
Milind Dattatraya Sindkhedkar
Manojkumar Ramprasad Shukla
Sachin Sethi
Pradeep Rangrao Patil
Dagadu Dube
Prathap Sreedharan Nair
Sudhakar Maruti Balgude
Venkata P Palle
Rajender Kumar Kamboj
Pradip Balu Wagh
Original Assignee
Lupin Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Lupin Ltd filed Critical Lupin Ltd
Publication of CR20220312A publication Critical patent/CR20220312A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/496—Non-condensed piperazines containing further heterocyclic rings, e.g. rifampin, thiothixene or sparfloxacin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/517—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with carbocyclic ring systems, e.g. quinazoline, perimidine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
    • C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04—Ortho-condensed systems
    • C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/10—Spiro-condensed systems
    • C07D491/107—Spiro-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)

Abstract

Se divulgan compuestos de fórmula general (I), su forma tautomérica, su estereoisómero, su sal farmacéuticamente aceptable, su polimorfo o solvato del mismo, en donde, el anillo A, de R1 a R5, X, Y, m, y n son como se definen en el presente documento, para su uso como inhibidores de SOS1 en el tratamiento de enfermedades o trastornos proliferativos infecciosos y rasopatías. También 10 se divulgan métodos para sintetizar el compuesto de fórmula I, composiciones farmacéuticas que contienen el compuesto de fórmula I, un método para el tratamiento de enfermedades o trastornos proliferativos, infecciosos o rasopatías, por ejemplo, un cáncer, administrando dicho compuesto y combinaciones del compuesto de fórmula I con otros principios activos.
CR20220312A 2019-11-29 2020-11-28 Compuestos tricíclicos sustituidos CR20220312A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN201921049157 2019-11-29
IN202021035414 2020-08-17
PCT/IB2020/061248 WO2021105960A1 (en) 2019-11-29 2020-11-28 Substituted tricyclic compounds

Publications (1)

Publication Number Publication Date
CR20220312A true CR20220312A (es) 2022-08-05

Family

ID=73856201

Family Applications (1)

Application Number Title Priority Date Filing Date
CR20220312A CR20220312A (es) 2019-11-29 2020-11-28 Compuestos tricíclicos sustituidos

Country Status (29)

Country Link
US (1) US12435066B2 (es)
EP (1) EP4065575B1 (es)
JP (1) JP7629922B2 (es)
KR (1) KR20220110241A (es)
CN (1) CN114746411B (es)
AU (1) AU2020393205A1 (es)
BR (1) BR112022010383A2 (es)
CA (1) CA3154914A1 (es)
CL (1) CL2022001392A1 (es)
CO (1) CO2022008997A2 (es)
CR (1) CR20220312A (es)
DK (1) DK4065575T3 (es)
EC (1) ECSP22050936A (es)
ES (1) ES2982576T3 (es)
FI (1) FI4065575T3 (es)
HR (1) HRP20240547T1 (es)
HU (1) HUE066732T2 (es)
IL (1) IL292721A (es)
LT (1) LT4065575T (es)
MX (1) MX2022006475A (es)
PE (1) PE20221336A1 (es)
PH (1) PH12022551014A1 (es)
PL (1) PL4065575T3 (es)
PT (1) PT4065575T (es)
RS (1) RS65526B1 (es)
SI (1) SI4065575T1 (es)
SM (1) SMT202400273T1 (es)
WO (1) WO2021105960A1 (es)
ZA (1) ZA202206253B (es)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2021249475A1 (zh) * 2020-06-10 2021-12-16 江苏恒瑞医药股份有限公司 稠合喹唑啉类衍生物、其制备方法及其在医药上的应用
MX2023003060A (es) 2020-09-15 2023-04-05 Revolution Medicines Inc Derivados indolicos como inhibidores de ras en el tratamiento del cancer.
MX2023008460A (es) * 2021-01-19 2023-09-12 Lupin Ltd Combinaciones farmacéuticas de inhibidores de sos1 para el tratamiento y/o prevención del cáncer.
WO2022187236A1 (en) * 2021-03-02 2022-09-09 Viva Star Biosciences (Suzhou) Co., Ltd. Novel substituted tricyclic aza-heterocycles as sos1 inhibitors
EP4313151A1 (en) 2021-03-31 2024-02-07 Sevenless Therapeutics Limited Sos1 inhibitors and ras inhibitors for use in the treatment of pain
TWI807787B (zh) * 2021-04-19 2023-07-01 大陸商昆藥集團股份有限公司 苯並嘧啶三環衍生物及製備方法和應用
CN115490699B (zh) * 2021-06-19 2024-08-09 成都海博为药业有限公司 一种稠环化合物及其药物组合物和用途
WO2023287730A1 (en) * 2021-07-13 2023-01-19 Recurium Ip Holdings, Llc Tricyclic compounds
CN115677699B (zh) * 2021-07-23 2024-11-22 武汉誉祥医药科技有限公司 三并环化合物及其药物组合物和应用
US20240382475A1 (en) * 2021-08-30 2024-11-21 Zhejiang Hisun Pharmaceutical Co., Ltd. Quinazoline Derivative, Or Preparation Method Therefor And Use Thereof
AR127308A1 (es) 2021-10-08 2024-01-10 Revolution Medicines Inc Inhibidores ras
TW202340214A (zh) 2021-12-17 2023-10-16 美商健臻公司 做為shp2抑制劑之吡唑并吡𠯤化合物
CA3240780A1 (en) * 2021-12-17 2023-06-22 Zhenyu Wang Heterocyclic compound having anti-tumor activity and use thereof
CN116425796A (zh) * 2022-01-12 2023-07-14 如东凌达生物医药科技有限公司 一类嘧啶并杂环类化合物、制备方法和用途
EP4463454A1 (en) 2022-01-14 2024-11-20 Jazz Pharmaceuticals Ireland Limited Novel amine-substituted phthalazines and derivatives as sos1 inhibitors
JP2025504495A (ja) * 2022-01-21 2025-02-12 シェンチェン イオノヴァ ライフ サイエンス カンパニー リミテッド Ｒａｓシグナル伝達の調節因子としての縮合複素環式化合物
EP4227307A1 (en) 2022-02-11 2023-08-16 Genzyme Corporation Pyrazolopyrazine compounds as shp2 inhibitors
GB202203976D0 (en) 2022-03-22 2022-05-04 Jazz Pharmaceuticals Ireland Ltd Tricyclic phthalazines and derivatives as sos1 inhibitors
WO2023240263A1 (en) 2022-06-10 2023-12-14 Revolution Medicines, Inc. Macrocyclic ras inhibitors
CN116969944A (zh) * 2022-08-02 2023-10-31 北京福元医药股份有限公司 乙氨基取代的三环杂环化合物及其组合物、制剂和用途
KR20260005904A (ko) 2023-04-07 2026-01-12 레볼루션 메디슨즈, 인크. 매크로사이클릭 ras 억제제
CN121263418A (zh) 2023-04-07 2026-01-02 锐新医药公司 大环ras抑制剂
AU2024252105A1 (en) 2023-04-14 2025-10-16 Revolution Medicines, Inc. Crystalline forms of ras inhibitors, compositions containing the same, and methods of use thereof
KR20250172857A (ko) 2023-04-14 2025-12-09 레볼루션 메디슨즈, 인크. Ras 억제제의 결정형
AU2024359022A1 (en) * 2023-10-10 2026-04-09 Jazz Pharmaceuticals Research Uk Limited Cannabinoid compounds and uses thereof

Family Cites Families (18)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4501728A (en) 1983-01-06 1985-02-26 Technology Unlimited, Inc. Masking of liposomes from RES recognition
US5019369A (en) 1984-10-22 1991-05-28 Vestar, Inc. Method of targeting tumors in humans
US4837028A (en) 1986-12-24 1989-06-06 Liposome Technology, Inc. Liposomes with enhanced circulation time
IL112248A0 (en) * 1994-01-25 1995-03-30 Warner Lambert Co Tricyclic heteroaromatic compounds and pharmaceutical compositions containing them
WO1999043679A1 (en) * 1998-02-27 1999-09-02 Kyowa Hakko Kogyo Co., Ltd. Imidazoquinazoline derivatives
US7291725B2 (en) 2002-06-26 2007-11-06 Chiron Corporation Sos1 inhibitors
US20070065622A1 (en) 2005-09-22 2007-03-22 Scientific Technologies Incorporated Safety Mat Active Joining Trim
WO2011075517A1 (en) 2009-12-17 2011-06-23 Merck Sharp & Dohme Corp. Aminopyrimidines as syk inhibitors
AU2014227824B2 (en) * 2013-03-15 2018-09-27 Dana-Farber Cancer Institute, Inc. Stabilized SOS1 peptides
WO2016077793A1 (en) 2014-11-14 2016-05-19 Children's Hospital Medical Center Sos1 inhibitors for cancer treatment
CN109071560B (zh) 2016-02-12 2022-01-14 瓦洛健康公司 用作泛素特异性蛋白酶抑制剂的噻吩并吡啶甲酰胺
JP7219218B2 (ja) * 2016-12-22 2023-02-07 ベーリンガー インゲルハイム インターナショナル ゲゼルシャフト ミット ベシュレンクテル ハフツング 新規のベンジルアミノ置換キナゾリンおよびｓｏｓ１阻害剤としての誘導体
CA3056970A1 (en) * 2017-03-21 2018-09-27 Bayer Pharma Aktiengesellschaft 2-methyl-quinazolines
RS64167B1 (sr) 2017-12-21 2023-05-31 Boehringer Ingelheim Int Benzilamino supstituisani piridopirimidinoni i derivati kao sos1 inhibitori
CA3097231A1 (en) 2018-04-18 2019-10-24 Bayer Pharma Aktiengesellschaft 2-methyl-aza-quinazolines
WO2020180768A1 (en) 2019-03-01 2020-09-10 Revolution Medicines, Inc. Bicyclic heteroaryl compounds and uses thereof
CN113727758A (zh) 2019-03-01 2021-11-30 锐新医药公司 双环杂环基化合物及其用途

Also Published As

Publication number Publication date
US12435066B2 (en) 2025-10-07
ZA202206253B (en) 2023-01-25
CN114746411A (zh) 2022-07-12
HUE066732T2 (hu) 2024-09-28
PH12022551014A1 (en) 2023-03-13
CO2022008997A2 (es) 2022-07-19
PE20221336A1 (es) 2022-09-13
US20230013778A1 (en) 2023-01-19
HRP20240547T1 (hr) 2024-07-05
RS65526B1 (sr) 2024-06-28
SI4065575T1 (sl) 2024-06-28
KR20220110241A (ko) 2022-08-05
PL4065575T3 (pl) 2024-06-24
IL292721A (en) 2022-07-01
WO2021105960A1 (en) 2021-06-03
EP4065575B1 (en) 2024-01-31
JP7629922B2 (ja) 2025-02-14
MX2022006475A (es) 2022-09-07
ES2982576T3 (es) 2024-10-16
DK4065575T3 (da) 2024-04-15
AU2020393205A1 (en) 2022-06-30
CL2022001392A1 (es) 2023-03-17
FI4065575T3 (fi) 2024-05-02
ECSP22050936A (es) 2022-07-29
PT4065575T (pt) 2024-05-03
LT4065575T (lt) 2024-05-27
CA3154914A1 (en) 2021-06-03
EP4065575A1 (en) 2022-10-05
CN114746411B (zh) 2024-06-25
JP2023504113A (ja) 2023-02-01
SMT202400273T1 (it) 2024-09-16
BR112022010383A2 (pt) 2022-08-23

Similar Documents

Publication Publication Date Title
CR20220312A (es) Compuestos tricíclicos sustituidos
CO2022010460A2 (es) Compuestos tricíclicos sustituidos
AR126854A1 (es) Compuestos macrocíclicos para el tratamiento de cáncer
CO2022001094A2 (es) Pirrolo[2,3-b]pirazinas como inhibidores de hpk1 y uso de las mismas
CO2022001357A2 (es) Inhibidores de shp2 fosfatasa de tipo pirazolo[3,4-b]pirazina
MX2023000410A (es) Analogos de rapamicina como inhibidores de mtor.
CY1124239T1 (el) Ενωσεις αμινο-τριαζολοπυριδινης και χρηση αυτων στην αγωγη του καρκινου
DOP2024000039A (es) Derivados de quinolina como inhibidores de la integrina alfa4beta7
CL2019002167A1 (es) Compuesto de la fórmula (ic) o una sal farmacéuticamente aceptable del mismo, o una composición farmacéutica que comprende dicho compuesto o una sal farmacéuticamente aceptable del mismo, y al menos un portador farmacéuticamente aceptable, y su uso en el tratamiento de disautonomía familiar al mejorar el empalme de marn. (divisional solicitud 201701823.)
MX2022004451A (es) Heteroaril-bifenil-amidas para el tratamiento de enfermedades relacionadas con el ligando pd-l1.
MX2020001235A (es) Análogos de 1,2-dihidro-3h-pirazolo[3,4-d]pirimidin-3-ona.
UY36207A (es) Inhibidores de la syk
ES3060268T3 (en) Bcl6 inhibitors
MX2021010122A (es) Compuestos de imidazopiridinilo y su uso para el tratamiento de trastornos neurodegenerativos.
MX2022007171A (es) Compuestos cíclicos y métodos de uso de estos.
MX2022005775A (es) Compuestos terapeuticos y metodos de uso.
UY39625A (es) Derivados tricíclicos útiles como inhibidores de parp7
UY39181A (es) COMPUESTOS Y COMPOSICIONES PARA INHIBIR LA ACTIVIDAD DE HIF2a Y SUS MÉTODOS DE USO
MX2023004998A (es) Metodo para tratar canceres con derivados de quinazolina sustituida con alquino.
EA201991355A1 (ru) Производные имидазо[1,5-а]пиразина в качестве ингибиторов pi3kдельта
MX2025002817A (es) Compuestos para el tratamiento del cancer
MX2018013325A (es) Derivados de adenina como inhibidores de proteína quinasa.
PH12021552953A1 (en) Tricyclic compounds
CO2022006942A2 (es) Compuestos de 1,8-naftiridin-2-ona para el tratamiento de una enfermedad autoinmunitaria
AR133167A1 (es) Macrociclos para el tratamiento de enfermedad autoinmunitaria